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ABSTRACT 
Purpose Up to 50% of urinary tract infections (UTIs) in young children are missed in primary care. Urine 
culture is essential for diagnosis, but urine collection is often difficult. Our aim was to derive and internally 
validate a two-step clinical rule using (1) symptoms and signs to select children for urine collection; and (2) 
symptoms, signs and dipstick testing to guide antibiotic treatment. 
Methods We recruited acutely unwell children <5 years from 233 primary care sites across England and 
Wales. Index tests were parent reported symptoms; clinician reported signs; urine dipstick results; and 
clinician opinion of UTI likelihood (͚ĐliŶiĐal diagŶosis͛Ϳ prior to dipstick and culture. The reference standard 
was microbiologically confirmed UTI cultured from a clean catch urine sample. We calculated sensitivity, 
specificity and area under the receiver operator characteristic (AUROC) curve of coefficient-based (graded 
severity) and points-based (dichotomised) symptom/sign logistic regression models and internally validated 
the AUROC using bootstrapping. 
Results 3036 children provided urines and culture results were available for 2740 (90%). Of these 60 (2.2%) 
were positive: ͚ĐliŶiĐal diagŶosis͛ ǁas ϰϲ.ϲ% seŶsitiǀe with AUROC of 0.77. Previous UTI, increasing 
pain/crying on passing urine, increasingly smelly urine, absence of severe cough, increasing clinician 
impression of severe illness, abdominal tenderness on examination and normal ear examination were 
associated with UTI. The validated coefficient (points) based model AUROCs were 0.87 (0.86), increasing to 
0.90 (0.90) by adding dipstick nitrites, leucocytes and blood. 
Conclusions A symptoms and signs based clinical rule is superior to clinician diagnosis and performs well for 
identifying young children for non-invasive urine sampling. Dipstick results add further diagnostic value for 
empiric antibiotic treatment. 
 
Words 265  
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INTRODUCTION 
The accurate and timely diagnosis of urinary tract infection (UTI) in children is important to alleviate short-
term suffering1 and prevent the possible long-term consequences such as renal scarring, impaired renal 
growth, recurrent pyelonephritis, impaired glomerular function, hypertension, end stage renal disease, and 
pre-eclampsia.2 3 4 Guidelines universally recommend urine sampling for microbiological confirmation, by 
clean catch (preferred in Europe),5 or catheterization or suprapubic aspiration (SPA) for unwell children 
where clean catch is not immediately available (preferred in the US6 and Australia7).   
There are three possible explanations why half of UTIs are not diagnosed at the earliest opportunity in UK 
primary care.8 First, there is a paucity of primary care relevant evidence regarding which children should be 
suspected. Guidelines, which emphasise the importance of fever,6 7 9 are largely informed by studies 
conducted in emergency departments.10 11 12 Second, the symptoms and signs of UTI are often non-specific, 
especially in very young children. Finally, obtaining an uncontaminated sample can be challenging, time-
consuming, and for invasive catheter and SPA sampling methods, painful,13 frightening14 and induce 
infection.15 
We report a large, prospective cohort study designed to investigate the diagnostic features of UTI in young 
children presenting to primary care. Our aim was to develop and internally validate a two-step clinical rule: 
step 1 used symptoms and signs to select children for urine sampling and step 2 (once urine was obtained) 
used symptoms, signs and dipstick testing to guide empiric antibiotic treatment. ͚CoeffiĐieŶt͛ aŶd ͚poiŶts͛ 









͚DUTY͛ was a multicenter, prospective, diagnostic cohort study recruiting children presenting to National 
Health Service (NHS) primary care sites. General Practitioners (GPs), nurses and childreŶ͛s emergency 
department (CED) doctors ;froŵ here oŶ ͚ĐliŶiĐiaŶs͛Ϳ ǁorkiŶg iŶ priŵarǇ Đare sites ;GP clinics, CEDs and 
Walk-in Centres) are the clinicians who provide primary care for children. Primary care sites were recruited 
and trained by four UK centre hubs (Bristol, Cardiff, London and Southampton).  
Participants  
Children were eligible if presenting with any acute (<28 days) illness episode, where the illness was 
associated with: (a) at least one constitutional symptom or sign identified by the National Institute of 
Health and Clinical Excellence (NICE)5 as a potential marker for UTI (fever, vomiting, lethargy/malaise, 
irritability, poor feeding and failure to thrive); and/or (b) at least one urinary symptom identified by NICE5 
as a potential marker of UTI (abdominal pain, jaundice (children <3 months only), hematuria, offensive 
urine, cloudy urine, loin pain, frequency, apparent pain on passing urine and changes to continence). As a 
result, constitutionally unwell children consulting with an apparently obvious cause for their symptoms 
(such as acute otitis media or bronchiolitis, without a urinary symptom) were included. Children were 
excluded if: constitutionally well (e.g. acute conjunctivitis only); neurogenic or surgically reconstructed 
bladder; permanent or intermittent urinary catheter; trauma as the main presenting problem; or antibiotics 
had been taken within seven days. Clinicians were asked to recruit consecutive eligible children and where 
this was not possible to log ĐhildreŶ͛s age and gender. 
Index tests and urine collection 
Following consent, 107 index tests (symptoms, signs and dipstick results, Web Table 1) were recorded on a 
standardised Case Report Form by qualified clinicians blind to the reference standard. Parent-reported 
items included the Đhild͛s medical history and symptoms. Signs, from a full clinical examination, included 
ĐliŶiĐiaŶs͛ global illness severity impression (zero to ten) and abdominal tenderness. Before urine dipstick 
testing, clinicians recorded their rating of UTI likelihood ;͚ĐliŶiĐal diagŶosis͛Ϳ. 
Our preferred urine collection method ǁas ͚ĐleaŶ ĐatĐh͛. For toilet trained children, we used a sterile bowl 
that the parent could hold under the child or put in a potty. For other children, the parent cleaned the 
nappy area using water alone and sat the child on their knee with the bowl placed under their perineum. If 
it was not possible to obtain a sample at the site, the parent was given equipment and advice on taking the 
sample at home. Where clean catch was not feasible, we used NICE-recommended ͚NeǁĐastle NappǇ Pads͛ 
(a sterile pad placed inside the diaper),5 but because of differences in contamination rates and ĐhildreŶ͛s 
ages between clean catch and nappy pad samples, the current analysis focuses on clean catch samples. 
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Urine samples were tested at the site using Siemans/Bayer multistix 8SG dipsticks. Urine samples were split 
into two fractions for microbiological analysis. The priority fraction was sent to the site͛s usual laboratory. 
When at least 1ml was left, the remainder was sent using first class postal SafeboxesTM in boric acid 
monovettes to the Public Health Wales Microbiology Specialist Antimicrobial Chemotherapy Unit in Cardiff 
(the ͞research laboratory͟Ϳ. 
Reference standard  
The reference standard was determined at the research laboratory, which spiral plated (Don Whitley, 
United Kingdom (UK)) 50μL of urine onto chromogenic agar and standard blood agar. Quantitative total 
counts were recorded for up to six organisms and the presence of antimicrobial substances measured. 
Samples were processed by two staff members using a single, standardised procedure. As per UK 
guidelines,16 our microbiological definition of UTI was either the ͚pure͛ ;single) or ͚predoŵiŶaŶt͛ growth of a 
uropathogen (an Enterobacteriaceae) at ≥ϭϬ5 Colony Forming Units (CFU)/mL. We defiŶed ͚predoŵiŶaŶt͛ 
growth as ≥ϭϬ5 CFU/ŵL of a uropathogeŶ ǁith ≥ϯ log10 (1000-fold) difference between the growth of this 
and the next species. For comparison, we used the United States (US) definition6 of a pure uropathogen 
growth >50,000 CFU/ml with ≥25 white blood cells/mm3 on microscopy or leucocyte positive (threshold at 
nil/trace) on dipstick. 
Sample size calculation  
We assumed a candidate predictor prevalence of 10% and UTI prevalence of 2%.17 With 80% power and a 
two-sided alpha of 5%, 3000 urine results were required to detect an odds ratio of 2.4 while 3100 results 
would give a clinical rule with 80% sensitivity a 95% CI width of 10%. We originally proposed to recruit 4000 
children with a target of recovering urines from at least 3,100 (77.5%) for clinical rule derivation and a 
further 2000 children for external validation. However, we did not anticipate the need to stratify analyses 
by clean catch/diaper pad collection method. We therefore decided to use all available clean catch results 
to derive the models, with internal bootstrap validation instead of external validation. 
Statistical analysis 
We compared the age and gender of the children who were recruited with those children whose parents 
declined to participate. We used logistic regression to estimate associations of index tests with urine 
culture positivity. Where categorical variables had one category with very few observations, we examined 
the frequency of symptom and sign categories blind to association with urine culture results and merged 
the least frequent categories prior to analyses. P values were derived using likelihood ratio tests. For 
ordinal variables, both heterogeneity and trend p values were derived. Continuous variables were divided 
into quintiles and trend p values were derived using the median within categories. We examined plots of 
the log odds of culture positivity against the median within quintiles for evidence of non-linearity. We used 
two methods for dealing with missing data, iŶĐludiŶg ͞doŶ͛t kŶoǁ͟ responses. First, missing data were 
coded as the modal non-missing value. Second, we repeated multivariable analyses using the chained 
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equations approach to multiple imputation: estimates and Wald p values18 based on 50 imputed datasets 
were deriǀed usiŶg ‘uďiŶ͛s rules.19  A complete case analysis was not feasible due to the reduction in 
sample size. 
Step 1 - symptoms and signs 
We derived ͚ĐoeffiĐieŶt-ďased͛ models in two stages. First, we selected symptoms and signs with either 
trend or heterogeneity univariable p values <0.01. Second, we derived models from selected symptoms and 
signs using backwards stepwise selection and an exclusion criterion of heterogeneity p value >0.1. We 
investigated using more liberal p value thresholds of 0.1 and 0.2 at the first stage, and found no important 
diagnostic utility differences of the final models (results available on request).  
We generated ͚poiŶts-ďased͛ models (easy to calculate without a computer) by dichotomising parent-
reported symptom variables to ͚preseŶt/aďseŶt͛, except for Đough ǁhiĐh ǁas diĐhotoŵised at ͚seǀere/all 
other categories͛ and ĐliŶiĐiaŶs͛ global illness severity impression at ≥ϲ threshold. We removed other 
physical examination variables as these contributed least to the models. We derived the points by dividing 
each coefficient by the smallest coefficient in the model and rounding to the nearest integer. 
We quantified diagnostic accuracy using the area under the receiver operating characteristic (AUROC) curve 
with 95% confidence interval. We internally validated coefficient-based models using the bootstrap 
procedure described by Steyerberg:20 we calculated a validated AUROC and a calibration slope (shrinkage 
factor) by which we multiplied model coefficients in order to derive internally validated odds ratios. 
Because ͚poiŶts-ďased͛ ŵodels haǀe fiǆed ĐoeffiĐieŶts such internal validation is not possible: instead we 
internally validated these models before rounding the coefficients. For each model, we selected linear 
predictor cut-points corresponding to a range of values for sensitivity, and then calculated the 
corresponding specificity, negative and positive predictive values, and proportion of children classified 
positive, with 95% confidence intervals. Model diagnostic parameters ǁere Đoŵpared agaiŶst ͚clinical 
diagnosis͛ of UTI ;ǁhere ĐliŶiĐiaŶs ĐoŶsidered UTI to ďe ͚fairlǇ͛ or ͚ǀerǇ͛ certain). In a sensitivity analysis we 
fitted the coefficient models in data restricted to children under three years of age. 
“iŶĐe ĐhildreŶ preseŶtiŶg ǁith ͚feǀer of uŶkŶoǁŶ origiŶ͛ is a group of partiĐular ĐliŶiĐal interest, we 
investigated the presence of UTI among children identified as having fever without symptoms or signs 
suggestive of another source. We used three ͚feǀer͛ ǀariaďles (pareŶt reported ͚feǀer Ŷoǁ or iŶ the past Ϯϰ 
hours͛, pareŶt reported ͚feǀer at aŶǇ tiŵe duriŶg this illŶess͛ aŶd teŵperature ≥ϯ8°C oŶ eǆaŵiŶatioŶ) 
combined with symptoms and signs regarded as evidence of a non-UTI illness (rash, diarrhoea, 
blocked/runny nose, cough, wheeze, shortness of breath, chest pain, earache, sore throat, oxygen 




Step 2 - symptoms, signs and dipstick testing 
We used the model development processes described in step 1, extending the symptoms and signs models 
to include dipstick results, with the points-based model dipstick results dichotomised at the ͚Ŷegative 
/positiǀe͛ threshold. To assess the added value of dipsticks over symptoms and signs alone we first 
quantified the change in AUROC and second, used a simulation approach based on the step 1 points-based 
model together with multinomial logit models in which dipstick results were predicted by the dichotomised 
symptoms and signs as predictors. The simulation procedure: (i) sampled coefficient values from the 
multivariate normal distribution of the multinomial logit parameter estimates; (ii) randomly generated a set 
of dipstick results based on the sampled coefficients; and (iii) computed the corresponding probability of 
UTI based on the shrunken coefficients for the symptoms, signs and dipstick points-based model. For each 
combination of symptoms and signs we generated 10,000 samples and calculated the probability of UTI 
with and without the dipstick results and the change in probability of UTI after accounting for the dipstick 
results. One of the dipstick combinations was dropped since it was observed in only three individuals and 
led to numerical instability. 
Effects of replacing US with UK UTI definition 
We calculated the prevalence and bias adjusted kappa statistic to assess agreement between UK and US 
UTI definitions21 and used crude and adjusted odds ratios, and the AUROC to assess strength of association, 






Between April 2010 and April 2012, 516 staff (61 research nurses; 182 GPs; and 273 site nurses) recruited 
participants from 233 primary care sites (225 GP practices, four Walk-in centers and four CEDs) across 
England and Wales. Of 10138 children screened potentially eligible, 1276 (12.6%) declined participation, 
1684 (16.6%) could not be recruited for other reasons and 15 (0.15%) withdrew (Web Figure 1). Urine was 
collected using clean catch from 3036 children, with reference standard (research laboratory) results 
available for 2740 (90%). Of these, 2561 (93%) were two years or older and 1473 (54%) female (Table 1). 
The most common working diagnoses were upper respiratory tract infection (28%), viral illness (15%), otitis 
media (10%) and gastroenteritis (3.6%). 
Sixty (2.2%) children met the laboratory definition for UTI: 50 (83.3%) with Escherichia coli; 5 (8.3%) with 
Proteus species; 3 (5.0%) with Klebsiella species; 1 (1.7%) with Morganella morganii and 1 (1.7%) with 
Citrobacter farmeri. 2627 (96%) samples were provided within 24 hours of index test measurement. Urinary 
antimicrobial substances were found in 128 (4.5%) samples and in 4 (6.7%) of the UTI positive samples. A 
͚clinical diagnosis͛ of UTI prior to urine dipstick testing was made in 168 (6.1%) children, of whom 28 
(16.7%) were UTI positive. ͚Clinical diagnosis͛ achieved 46.6% sensitivity, 94.7% specificity and AUROC 0.77 
(95% CI 0.71 to 0.83). Missing data and ͚not known͛ responses were infrequent (Table 1).  
Step 1 - symptoms and signs 
The parent-reported index tests associated with UTI in crude (Table 1) and adjusted (Table 2) analyses were 
pain/crying while passing urine, smelly urine, previous UTI and absence of severe cough. For the first two, 
there was a graded association with increasing symptom severity. Clinician-reported index tests associated 
with UTI were increasing illness severity (graded association), abdominal tenderness and absence of ear 
abnormalities. None of the other index tests (Web Table 1) met our criteria for model inclusion, and there 
was no evidence of association for fever of unknown origin (Web Table 3) or prior illness duration (data not 
shown). 
The multiple imputation-based AUROC for the coefficient-based step 1 model was 0.89 (95% CI 0.85 to 
0.95, internally validated AUROC 0.88, Table 2, Figure 1). To achieve sensitivities of 70% (all children with 
liŶear prediĐtor ≥-2.729) or 85% ;liŶear prediĐtor ≥-3.717) with the step 1 model would require urine 
sampling in 6.8% to 17.6% of children (Table 3, upper); with corresponding positive predictive values of 
22.6% to 10.6% and specificities of 94.6% to 83.9%. While the points-based model had a similar AUROC 
0.86 (95% CI 0.81 to 0.90, validated 0.85, Web Table 2) to the coefficient-based model, other diagnostic 
parameters were inferior: using an 85.0% sensitivity (≥ϯ point cut-off) only increased the post-test 
probability to 6.9%, with a lower specificity (74.4%) and higher (26.9%) urine collection rate (Web Table 4, 
upper). Using a ≥ϱ point cut-off ;͞aŶǇ three of fiǀe͟ sǇŵptoŵs aŶd sigŶsͿ increased the post-test UTI 
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probability to 17.7%, with increased specificity (94.6%) and reduced urine collection rate (6.4%), but at the 
expense of reduced sensitivity (51.7%, Web Table 4 (upper) and Figure 2).  
Urine samples were available for 88, 91 and 612 children <12, 12 to 23, and 24 to 35 months with 
laboratory confirmed UTI in 4, 2 and 16 of these children respectively (Table 1). The coefficient model 
performed well in children under 3 years, with similar estimated odds and AUROC (Web Table 5). 
Step 2 - symptoms, signs and dipstick testing 
Dipstick leukocytes, nitrites, and blood were strongly associated with UTI (Tables 1 and 2). The coefficient-
based, multiple imputation model AUROC was 0.93 (95% CI 0.90 to 0.97, validated 0.90), an increase of 
0.034 (p=0.009) when dipstick results were added to symptoms and signs (Table 2, Figure 1). If all children 
had a urine sample and dipstick test, the dipstick test results could maintain sensitivity at 80% while 
improving specificity from 88.3% to 93.8% and reducing the percentage of children treated with antibiotics 
from 13.2% to 7.8%, assuming immediate antibiotic use (Table 3). The points-based model AUROC was 0.90 
(95% CI 0.85 to 0.95, validated 0.89), and increased (by 0.045, p=0.003) when dipstick results were added 
to symptoms and signs (Table 4).  
Results of the simulation study showed a clear trend towards increased diagnostic value of dipstick results 
(change in probability of UTI) as the step 1 (symptoms and signs) based probability of UTI increased (Web 
Table 7). In children with a relatively low (<5%) step 1 probability of UTI (points score <5), the median 
absolute change in post-test UTI probability with dipstick results was 0.3%, and only exceeded 4% in 2.5% 
of simulations. In children with a higher ;≥ϱ%Ϳ step 1 UTI probability (points sĐore ≥ϱͿ, the dipstiĐk results 
had a larger impact on the UTI probability (median post-test probability change 9.9%).  
Serious adverse events 
79 (1.1%) of the 7163 recruited children were hospitalized, three related to dipstick testing (two with UTI 
and one with diabetes).  
Effects of replacing US with UK UTI definition 
Data were available for all 2740 (100%) children, 35 (1.3%) of whom were UTI positive using the US UTI 
definition. We found good agreement (prevalence and bias adjusted kappa = 0.98), and crude and adjusted 
odds ratios were similar, comparing US and UK UTI definitions, showing the same graded associations, 
except for ͚seǀere Đough͛ (adjusted odds ratio 0.74 (0.23 to 2.37) US compared with 0.29 (0.09 to 0.97) UK, 
data available from the authors). Step 1 and step 2 diagnostic utilities were stable to the US definition, with 
validated AUROCs of 0.882 and 0.925 respectively.   
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DISCUSSION 
Summary of findings  
In a large cohort of young children presenting with acute illness to primary care, 2.2% of clean catch urine 
samples met the microbiological criteria for UTI. Based on data obtained from clean catch samples, we 
developed novel coefficient (for computer use) and points-based clinical rules to help clinicians identify 
children for urine sampling and antibiotic treatment with high diagnostic utility. For step 1, the coefficient-
based rule was diagnostically superior to the points-based rule, which in turn, was superior to clinical 
diagnosis. For step 2, dipstick testing was diagnostically superior to symptoms and signs alone (both 
coefficient and points-based rules), and was not diagnostically useful in children with the lowest UTI 
probability, in whom step 1 would not result in urine collection. 
Strengths and limitations  
To our knowledge, this is the largest and most rigorous diagnostic accuracy study of UTI in children under 
five years in primary care. Participating children were similar to those invited but declining. We achieved 
high levels of data completeness across a large number of primary care sites and maintained blinding of 
recruiting staff to the reference standard. Index tests were measured according to routine clinical practice 
using standardised reporting forms and equipment, and nearly all were completed within 24 hours of urine 
sample retrieval, minimising disease progression bias. The low number of samples with antimicrobial 
substances minimises treatment paradox. Our reference standard was specific to common uropathogens, 
and excluded index tests. Two members of staff, blind to all index tests bar age, performed the 
microbiological cultures and interpreted results, using a standardised process in a single laboratory. Our 
broad eligibility criteria allowed us to identify previously unidentified clinical features useful for both 
increasing (smelly urine) and decreasing (absence of severe cough, normal ear examination) UTI 
probability, as well as demonstrate the absence of diagnostic utility of other features (such as fever, fever 
of unknown origin, vomiting, lethargy, irritability and poor feeding) widely believed5 6  to be diagnostically 
useful. Our results are stable using the more conservative US definition of UTI. 
The main limitation is the relatively small number of UTI diagnoses, especially in the youngest children, 
which impacted on three areas. First, we were not able to externally validate our rules. While external 
validation is desirable prior to clinical application, bootstrap validation takes account of model over-
optimism. By analogy, it is reasonable for clinical practice to change on the basis of a single, well conducted 
randomised trial, though replication is desirable. That said, since we recruited from ͚first-point-of-contact͛ 
primary care sites, we consider it necessary to evaluate the rule͛s performance prior to use in secondary 
care. Second, our rule development breached the widely quoted ͞ϭϬ eǀeŶts per ĐaŶdidate prediĐtor͟. 
However, this rule of thumb has little theoretical or empirical justification: the consequences of variable 
selection are strongly dependent on the strength of association of candidate predictors with the outcome. 
Here, predictors of UTI are biologically plausible and associations substantial. Finally, children under two 
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years are under-represented in these analyses because of the difficulty of obtaining clean catch samples in 
this age group. However, we found our rule to be diagnostically accurate in children under three years and 
we know of no reason why the symptoms and signs identified in our study would not generalise to younger 
age groups. Our secondary care experience, and a recent report describing a bladder stimulation technique 
for infants,22 suggest that when sufficient time, space and personnel are available, clean catch sampling is 
possible in most young children.  
We mitigated the impact of false positive urine cultures (arising as a result of asymptomatic bacteriuria23 or 
contamination) using three design features. First, children were only eligible if experiencing constitutional 
and/or urinary symptoms; second, the rule was developed only using clean catch samples; and third, we 
used a single research laboratory, which used methods superior to NHS laboratories to distinguish 
contaminated urine. Incorporation bias could have inflated the AUROC for step two using the US definition 
of UTI since dipstick leucocytes were used as both an index test and within reference standard definition. 
Results in context with other studies 
One systematic review of eight primary studies (7892 children),24 and five primary studies10 11 25 26 27 of a 
further 18,796 children (with only one25 conducted in GP surgeries) have assessed UTI prevalence and the 
diagnostic value of clinical symptoms and signs in children <5 years.28 These found similar UTI prevalence 
and showed abdominal pain, back pain, dysuria, frequency, and new-onset urinary incontinence were 
positively associated with UTI.24 Stridor, audible wheeze, circumcision, temperature <39°C with a source, 
abnormal chest sounds, chest crackles, age under three years, not feeling hot, and rapid breathing were 
inversely associated with UTI. The largest study, which included 16,000 children presenting to the CED, 
derived a complex model based on 27 symptoms and signs, with an AUROC of 0.80 (95% CI 0.78 to 0.82).26 
The only previous study to recruit from GP surgeries found that younger age, urinary frequency and 
pain/crying on passing urine were associated with UTI, but had insufficient children with UTI to develop a 
clinical rule.25 Previous investigation of malodorous urine has shown conflicting results,27 29 but our study 
strongly supports its diagnostic value. Dipstick testing has been considered diagnostically unhelpful in 
young children.5 
Clinical and research implications 
In keeping with recently updated US guidelines,6 our results support a ŵore sophistiĐated ͚risk-based͛ 
approach to the identification of children for investigation of UTI. Pain or crying while passing urine, smelly 
urine, previous UTI, absence of severe cough, abdominal tenderness, and absence of ear abnormalities can 
be used for deciding which children to urine sample (step 1) and dipstick results to improve specificity for 
antibiotic treatment (step 2). For both steps, increasing diagnostic sensitivity can be achieved by increasing 
urine sampling rates, which may not be feasible or affordable. The clinical rules can be used (Figure 2) by 
clinicians with a wide range of experience, and focus attention on predictive factors rather than those (such 
as fever) with poor diagnostic utility. Clinicians concerned about over-diagnosis and treatment could select 
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a higher specificity threshold, while higher sensitivity thresholds would reduce under-diagnosis. The rule 
should supplement not replace clinical judgement. 
Further research is needed to distinguish pathogens from contamination and asymptomatic bacteriuria.23 
Given the expense of an external validation study, and the low rates of routine urine sampling (which 
render routine datasets unsuitable), we consider the most cost-effective future research strategy would be 
to assess the impact of the DUTY clinical rule on clinical behaviour and patient outcome in a randomised 
trial, and that the strongest design would integrate the presentation of the coefficient-based clinical rule 
within routine clinical care, probably via electronic medical records.  
CONCLUSIONS  
Our rule can be used to enhance current clinical practice in the identification of young children for non-
invasive urine sampling in primary care. Fever should not be used to stratify UTI probability and dipstick 
testing can be used to improve specificity for empiric antibiotic treatment in this population.  
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Table 1. ChildreŶ͛s ĐharaĐteristiĐs aŶd Đrude odds ratio for associations with UTI. 
Demographics and index 
tests* 




Gender Male 1267 (46.2%) 13 (1.0%) 1 (ref) 
 Female 1473 (53.8%) 47 (3.2%) 3.18 (1.71,5.90) 
Age of child <6 months 34 (1.2%) 1 (2.9%) 1.13 (0.15,8.77) 
 6 to <12 months 54 (2.0%) 3 (5.6%) 2.19 (0.62,7.77) 
 1 to <2 years 91 (3.3%) 2 (2.2%) 0.84 (0.19,3.70) 
 2 to <3 years 612 (22.3%) 16 (2.6%) 1 (ref) 
 3 to <4 years 1073 (39.2%) 21 (2.0%) 0.74 (0.39,1.44) 
 4 years plus 876 (32.0%) 17 (1.9%) 0.74 (0.37,1.47) 
Clinician diagnosis prior 
to dipstick 
Not UTI certain / v. certain 1149 (41.9%) 6 (0.5%) 0.28 (0.12,0.69) 
Not UTI fairly certain / uncertain 1417 (51.7%) 26 (1.8%) 1(ref) 
UTI fairly  to very certain  168 (6.1%) 28 (16.7%) 10.75 (6.13,18.8) 
Missing 6 (0.2%) 0 (0.0%)  
Pain/crying when passing 
urine* 
No problem 2234 (81.5%) 22 (1.0%) 1 (ref) 
Slight problem 182 (6.6%) 6 (3.3%) 2.97 (1.21,7.29) 
 Moderate problem 128 (4.7%) 12 (9.4%) 9.01 (4.45,18.2) 
 Severe problem 51 (1.9%) 15 (29.4%) 36.30 (17.81,74.0) 
 Missing/not known 145 (5.3%) 5 (3.4%)  
Smelly urine* No problem 2108 (76.9%) 20 (0.9%) 1 (ref) 
 Slight problem 174 (6.4%) 10 (5.7%) 5.87 (2.76,12.5) 
 Moderate problem 179 (6.5%) 16 (8.9%) 9.46 (4.93,18.2) 
 Severe problem 51 (1.9%) 10 (19.6%) 23.5 (10.6,52.3) 
 Missing/not known 228 (8.3%) 4 (1.8%)  
Cough* No problem 773 (28.2%) 24 (3.1%) 1 (ref) 
 Slight problem 556 (20.3%) 16 (2.9%) 0.93 (0.48,1.76) 
 Moderate problem 829 (30.3%) 17 (2.1%) 0.66 (0.35,1.23) 
 Severe problem 579 (21.1%) 3 (0.5%) 0.16 (0.05,0.54) 
 Missing/not known 3 (0.1%) 0 (0.0%)  
Previous UTI* No 2449 (89.4%) 43 (1.8%) 1 (ref) 
 Yes 177 (6.5%) 12 (6.8%) 3.81 (1.99,7.31) 
 Missing/not known 114 (4.2%) 5 (4.4%)  
Clinician global 
impression of illness 
severity (0-10)* 
0-1 989 (36.1%) 14 (1.4%) 1 (ref) 
2 739 (27.0%) 14 (1.9%) 1.35 (0.64,2.85) 
3 531 (19.4%) 14 (2.6%) 1.89 (0.89,4.00) 
4-5 363 (13.2%) 12 (3.3%) 2.39 (1.09,5.21) 
6 or more 115 (4.2%) 6 (5.2%) 3.85 (1.45,10.21) 
missing 3 (0.1%) 0 (0.0%)  
Abdominal exam: any 
tenderness* 
No 2237 (81.6%) 46 (2.1%) 1 (ref) 
Yes 63 (2.3%) 8 (12.7%) 7.34 (3.33,16.19) 
 Missing 440 (16.1%) 6 (1.4%)  
Ear exam: any acute 
abnormality* 
No 1783 (65.1%) 50 (2.8%) 1 (ref) 
Yes 635 (23.2%) 4 (0.6%) 0.23 (0.08,0.64) 
 Missing 322 (11.8%) 6 (1.9%)  
Dipstick: leukocytes* Negative 2272 (82.9%) 17 (0.7%) 1 (ref) 
 Trace 154 (5.6%) 6 (3.9%) 5.40 (2.10,13.9) 
 + 110 (4.0%) 2 (1.8%) 2.47 (0.56,10.8) 
 ++ 148 (5.4%) 19 (12.8%) 19.61 (9.95,38.6) 
 +++ 48 (1.8%) 16 (33.3%) 66.6 (30.9,143.3) 
 Missing 8 (0.3%) 0 (0.0%)  
Dipstick: nitrites* Negative 2658 (97.0%) 35 (1.3%) 1 (ref) 
 Positive 74 (2.7%) 25 (33.8%) 38.4 (21.4,68.9) 
 Missing 8 (0.3%) 0 (0.0%)  
Dipstick: blood* Negative 2297 (83.8%) 29 (1.3%) 1 (ref) 
 Non-heme 246 (9.0%) 8 (3.3%) 2.64 (1.19,5.84) 
 Heme trace 50 (1.8%) 6 (12.0%) 10.70 (4.23,27.08) 
 Heme + 67 (2.4%) 4 (6.0%) 4.98 (1.70,14.60) 
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Demographics and index 
tests* 




 Heme ++ or +++ 72 (2.6%) 13 (18.1%) 17.29 (8.56,34.94) 
 Missing 8 (0.3%) 0 (0.0%)  
* Index tests independently associated with UTI in multivariable models. Missing values were assigned to the modal category for 
crude OR. 
a All children column gives the percentage of observations within that category 
b Children with UTI column gives the percentage of positives relative to the number of observations within that category
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Table 2. Coefficient based modelsa for symptoms and signs; symptoms, signs and dipstick results; 
including results based on multiple imputation   
        Symptom and sign model     Symptom, sign and dipstick model 
Index tests Adjusted  ORa 
(95 % CI)b 
MIc adjusted ORa 
(95% CI) 
Adjusted  ORa 
(95 % CI)b 
MIc adjusted ORa 
(95% CI) 
Pain/crying when passing urine     
No problem 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Slight problem 1.56 (0.68,3.61) 1.73 (0.73,4.06) 1.01 (0.37,2.80) 1.16 (0.41,3.24) 
Moderate problem 4.58 (2.27,9.25) 4.80 (2.30,10.04) 2.68 (1.16,6.18) 2.87 (1.21,6.82) 
Severe problem 14.32 (6.81,30.11) 15.81 (7.37,33.89) 9.64 (3.92,23.69) 10.33 (4.11,25.96) 
Smelly urine     
No problem 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Slight problem 4.08 (2.00,8.33) 4.28 (2.02,9.05) 2.97 (1.29,6.85) 3.16 (1.32,7.59) 
Moderate problem 5.00 (2.64,9.48) 5.14 (2.60,10.19) 4.16 (2.02,8.57) 4.34 (2.00,9.39) 
Severe problem 8.49 (3.74,19.26) 8.76 (3.76,20.41) 4.13 (1.51,11.31) 4.44 (1.57,12.54) 
Previous UTI     
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Yes 2.71 (1.39,5.27) 2.66 (1.34,5.26) 2.39 (1.12,5.11) 2.36 (1.10,5.03) 
Cough     
No problem 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Slight problem 1.28 (0.67,2.45) 1.32 (0.68,2.55) 1.27 (0.59,2.72) 1.30 (0.60,2.81) 
Moderate problem 1.31 (0.69,2.48) 1.38 (0.72,2.68) 1.95 (0.95,4.00) 2.04 (0.98,4.22) 
Severe problem 0.28 (0.08,0.93) 0.29 (0.09,0.97) 0.36 (0.09,1.48) 0.36 (0.09,1.51) 
Clinician global impression of illness severity (0-10)   
0-1 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
2 1.97 (0.95,4.12) 1.98 (0.93,4.19) 2.14 (0.93,4.91) 2.13 (0.92,4.97) 
3 2.66 (1.28,5.54) 2.72 (1.28,5.81) 2.65 (1.16,6.07) 2.63 (1.13,6.14) 
4-5 3.57 (1.61,7.91) 3.87 (1.72,8.73) 2.96 (1.18,7.42) 3.24 (1.28,8.24) 
6 or more 6.84 (2.52,18.56) 7.24 (2.59,20.25) 5.80 (1.81,18.60) 6.28 (1.92,20.61) 
Abdominal exam: any tenderness     
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Yes 2.40 (1.03,5.61) 2.24 (0.95,5.25) 1.34 (0.40,4.45) 1.18 (0.35,3.94) 
Ear exam: any acute abnormality     
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 
Yes 0.30 (0.11,0.83) 0.27 (0.10,0.74) 0.46 (0.18,1.22) 0.40 (0.15,1.09) 
Dipstick: leukocytes     
Negative   1 (ref) 1 (ref) 
Trace   1.81 (0.68,4.81) 1.78 (0.66,4.78) 
+   0.70 (0.16,3.13) 0.66 (0.14,3.12) 
++   5.27 (2.52,11.04) 5.19 (2.45,10.98) 
+++   10.45 (4.11,26.53) 10.36 (3.94,27.26) 
Dipstick: nitrites     
Negative   1 (ref) 1 (ref) 
Positive   5.25 (2.56,10.77) 5.37 (2.58,11.19) 
Dipstick: blood     
Negative   1 (ref) 1 (ref) 
Non-heme   0.88 (0.36,2.17) 0.89 (0.35,2.21) 
Heme trace   4.16 (1.34,12.85) 4.08 (1.28,13.05) 
Heme +   2.65 (0.87,8.03) 2.84 (0.92,8.79) 
Heme ++ or +++   1.71 (0.65,4.51) 1.74 (0.64,4.73) 
Area under ROC curve (95% CI)d 0.892 (0.84,0.94) 0.899 (0.85,0.95) 0.926 (0.89,0.96) 0.933 (0.90,0.97) 
Validated area under ROC curve e 0.871 0.876 0.904 0.903 
Calibration slopee 0.865 0.871 0.832 0.832 
a Odds ratios calculated using shrunken estimates from the bootstrap internal validation calibration slope; b Missing values coded to 
modal category; c MI: multiple imputation; d Calculated without internal validation. e Calculated from the bootstrap internal 
validation  
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Table 3. Diagnostic test characteristics (95% CI) of coefficient based modelsa for a range of sensitivity cutpoints, using symptoms and signs model 














Percentage of children clinical 
rule positive 




-0.504 -0.195 20.0% (11.7%, 32.0%) 99.8% (99.5%, 99.9%) 66.7% (42.9%, 84.2%) 98.2% (97.7%, 98.7%) 0.7% (0.4%, 1.0%) 
-1.092 -0.87 30.0% (19.8%, 2.7%) 99.5% (99.1%, 99.7%) 56.3% (39.0%, 72.1%) 98.4% (97.9%, 98.9%) 1.2% (0.8%, 1.6%) 
-1.813 -1.698 40.0% (28.5%, 52.8%) 98.2% (97.6%, 98.6%) 32.9% (23.1%, 44.4%) 98.7% (98.1%, 99.0%) 2.7% (2.1%, 3.3%) 
-2.059 -1.98 50.0% (37.6%, 62.4%) 97.5% (96.9%, 98.1%) 31.3% (22.8%, 41.2%) 98.9% (98.4%, 99.2%) 3.5% (2.9%, 4.3%) 
-2.372 -2.34 60.0% (47.2%, 71.5%) 96.3% (95.5%, 97.0%) 26.7% (19.9%, 34.7%) 99.1% (98.6%, 99.4%) 4.9% (4.2%, 5.8%) 
-2.729 -2.75 70.0% (57.3%, 80.2%) 94.6% (93.7%, 95.4%) 22.6% (17.1%, 29.1%) 99.3% (98.9%, 99.6%) 6.8% (5.9%, 7.8%) 
-3.396 -3.515 80.0% (68.0%, 88.3%) 88.3% (87.0%, 89.4%) 13.3% (10.1%, 17.2%) 99.5% (99.1%, 99.7%) 13.2% (12.0%, 14.5%) 
-3.717 -3.884 85.0% (73.6%, 92.0%) 83.9% (82.4%, 85.2%) 10.6% (8.1%, 13.6%) 99.6% (99.2%, 99.8%) 17.6% (16.2%, 19.1%) 
-4.567 -4.86 93.3% (83.5%, 97.5%) 61.0% (59.1%, 62.8%) 5.1% (3.9%, 6.6%) 99.8% (99.4%, 99.9%) 40.2% (38.4%, 42.0%) 
-5.299 -5.7 96.7% (87.6%, 99.2%) 37.8% (35.9%, 39.6%) 3.4% (2.6%, 4.3%) 99.8% (99.2%, 100.0%) 63.0% (61.2%, 64.8%) 
-6.138 -6.664 100%  15.7% (14.4%, 17.1%) 2.6% (2.0%, 3.3%) 100%  84.6% (83.2%, 85.9%) 
Symptom, sign and dipstick model   Percentage antibiotic treatedd 
0.801 1.43 20.0% (11.7%, 32.0%) 99.9% (99.7%, 100.0%) 85.7% (57.3%, 96.4%) 98.2% (97.7%, 98.7%) 0.5% (0.3%, 0.9%) 
-0.122 0.321 40.0% (28.5%, 52.8%) 99.9% (99.7%, 100.0%) 88.9% (70.7%, 96.4%) 98.7% (98.2%, 99.0%) 1.0% (0.7%, 1.4%) 
-1.346 -1.15 60.0% (47.2%, 71.5%) 99.3% (98.8%, 99.5%) 64.3% (51.0%, 75.7%) 99.1% (98.7%, 99.4%) 2.0% (1.6%, 2.6%) 
-3.114 -3.275 80.0% (68.0%, 88.3%) 93.8% (92.9%, 94.7%) 22.5% (17.4%, 28.6%) 99.5% (99.2%, 99.7%) 7.8% (6.8%, 8.8%) 
-3.700 -3.98 83.3% (71.7%, 90.8%) 88.3% (87.0%, 89.5%) 13.8% (10.6%, 17.7%) 99.6% (99.2%, 99.8%) 13.2% (12.0%, 14.6%) 
-4.746 -5.237 96.7% (87.6%, 99.2%) 66.3% (64.5%, 68.1%) 6.0% (4.7%, 7.7%) 99.9% (99.6%, 100.0%) 35.0% (33.3%, 36.8%) 
-5.235 -5.825 98.3% (89.1%, 99.8%) 53.1% (51.2%, 54.9%) 4.5% (3.5%, 5.7%) 99.9% (99.5%, 100.0%) 48.1% (46.2%, 49.9%) 
-5.955 -6.69 100%  29.5% (27.8%, 31.2%) 3.1% (2.4%, 3.9%) 100%  71.2% (69.4%, 72.8%) 
a Results based on models using multiple imputation to deal with missing values 
b Derived from the coefficient based models using multiple imputation where the coefficients are listed within Web Table 5  
c Percentage of children who would be at or above this threshold assuming that all children had a urine sample  
d Percentage of children who would be at or above this threshold assuming that all children had a urine sample and dipstick test 
For ĐoŵparisoŶ, ͚ĐliŶiĐiaŶ diagŶosis͛ seŶsitiǀitǇ was 46.6% and specificity 94.7% 
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Figure 1. ROC curve for multiple imputation, coefficient-based models for clinician diagnosis 




















Figure 2. DUTY (Diagnosis of Urinary Tract infection in Young) Children Clean Catch Criteria
How to use the DUTY Clean Catch Urine Criteria 
1. The DUTY Clean Catch Urine Criteria are for children in whom a clean catch sample is possible. 
2. Urinary tract infection (UTI) was defined as ≥ϭϬ5 Colony Forming Units (CFU)/mL of a single or 
predominant uropathogen cultured from a clean catch urine specimen 
3. Table A: Use the symptoms and signs to decide if a clean catch urine should be collected/antibiotics 
given ;≥ϱ poiŶts or ĐaŶ ďe operatioŶalised as ͚any three of the five͛ sǇŵptoŵs aŶd sigŶs has ďeeŶ 
shown to be cost effective). Clinicians concerned about over-diagnosis and treatment can select a 
higher speĐifiĐitǇ ;at least siǆ poiŶtsͿ threshold. Higher seŶsitiǀitǇ thresholds ;e.g. ≥ϯ poiŶts or ≥4 
points) would reduce under-diagnosis, but these thresholds have not been shown to be cost effective. 
4. It is not clear which of the following possible antibiotic treatment strategies is most cost effective: (i) 
immediate presumptive treatment of all sampled children; (ii) immediate dipstick guided treatment; or 
(iii) laboratory guided (delayed) treatment. 
5. For ĐhildreŶ uriŶe saŵpled at the ≥ϱ poiŶt threshold, the proďaďilitǇ of UTI ǁill ďe ϭ8% (Web Table 3 
(upper)). Although not demonstrably cost-effective, dipstick testing can raise or lower this probability 
(see Table B).  
6. Table B: Refer to Web Table 3 (lower) for probability of UTI with total score 
7. Consider advising all (urine and non-uriŶe saŵpledͿ ĐhildreŶ͛s pareŶts to seek ŵediĐal adǀiĐe if their 
child gets worse  
8. The DUTY Clean Catch Urine Criteria are designed to supplement and not replace clinical judgement 
 
Table A: Should I get a urine sample?  
Clinical characteristic (present/absent)a POINTSb 
  
Symptoms and signs To guide urine collection 
Pain/crying passing urinec  2 
Smelly urinec  2 
Previous UTIc 1 
Absence of severe coughd 2 
Severe illness presente 2 
 
Collect clean catch urine if symptoms and signs points 
total ≥5 ͞any three of the five͟ 
 
Table B. Should I give antibiotic treatment? 
Clinical characteristic (present/absent)a POINTS 
  
Symptoms, signs and dipstick To guide antibiotic treatment 
Pain/crying passing urinec  2 
Smelly urinec  2 
Previous UTIc 1 
Absence of severe coughd 2 
Severe illness presente 2 
Dipstick: Leukocytes positive 2 
Dipstick: Nitrites positive 3 
Dipstick: Blood positive 1 
  
a Clinical characteristic wording as used in study Case Report Form and reported by parent/clinician unless stated otherwise 
b Refer to Web Table 3 (upper) for probability of UTI with total score  
c Parents were asked to report presence/absence 
d Parents were asked to grade presence of cough as no problem, slight problem, moderate problem or severe problem  
e “Đore of ≥ϲ oŶ the ĐliŶiĐiaŶ gloďal illŶess severity scale with range 0 (child completely well) to 10 (child extremely unwell). 
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